据新华社，记者26日从国药集团获悉，国药集团中国生物武汉生物制品研究所研发的全球首款口服六价 重配轮状病毒减毒活疫苗在武汉顺利完成首剂接种，这标志着我国在儿童疫苗研发与应用领域取得重要 突破，为儿童健康防护体系建设注入了新的动力。该产品通过严谨的临床试验验证，在安全性、有效性 等方面均达到国际先进疫苗水平，于2025年8月正式获得国家药监局批准上市，为我国预防用生物制品1 类新药，也是目前全球价次最高、覆盖最广的轮状病毒疫苗，为婴幼儿急性胃肠炎的预防提供了更加全 面的保护手段。 ...

Core Viewpoint - The recent advancements in vaccine development by China National Pharmaceutical Group's Wuhan Institute of Biological Products signify a crucial step in the country's efforts to combat major infectious diseases and enhance the self-reliance in high-end combination vaccines [1] Group 1: Vaccine Approvals - The Sabin strain inactivated poliovirus vaccine (Vero cell) has received approval for market launch from the National Medical Products Administration (NMPA) [1] - The combined vaccine for acellular pertussis, diphtheria, tetanus, inactivated poliovirus, and Haemophilus influenzae type b has been granted clinical trial approval [1]